ReviewCells2020
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 635 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
635 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,137 citations in OpenAlex.
- Tea and liver fibrosis: a bibliometric analysis of mechanisms, translational challenges, and emerging trends.Frontiers in nutrition · 2026Pooled it
- Trial
- Article
- Oral self-assembly nanoemulsion drivesDrug delivery · 2026Article
- Decoding fibroblast activation: Transcriptional networks in hepatic stellate cells and across fibrotic organs (Review).International journal of molecular medicine · 2026Review
- Ginsenosides alleviate the progression of hepatic fibrosis by targeting the liver circadian clock geneMolecular medicine reports · 2026Article
- Spectral CT predicts initial bleeding risk in cirrhotic patients with esophagogastric varices.Abdominal radiology (New York) · 2026Article
- [The role of hepatocyte programmed cell death in liver fibrosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Pharmacological Potential of Selenoproteins in the Regulation of Oxidative Stress in Liver Diseases.Pharmaceutics · 2026Review
- Gut Commensal Bacteria Ameliorate Liver Fibrosis by Inhibiting Macrophage M1 Polarization Through Secondary Bile Acids in a Murine Liver Fibrosis Model.Microorganisms · 2026Article
- Non-Selective β-Blocker Use and Portal Vein Thrombosis in Cirrhosis: An Updated Systematic Review and Meta-Analysis.Biomedicines · 2026Review
- Special Issue "Liver Fibrosis: Molecular Pathogenesis, Diagnosis and Treatment".International journal of molecular sciences · 2026Article
- Role of ATOH8 in Mitigating Cardiac Fibrosis in Heart Failure via Inhibition of the Transcriptional Repression of Smad7 by RUNX2.Biomolecules & therapeutics · 2026Article
- Subgroups of Adult-Onset Diabetes: A Prospective Follow-Up Study of Progression of Insulin Resistance and Deficiency and Association With Liver Steatosis and Fibrosis.Diabetes, obesity & metabolism · 2026Article
- MicroRNA Control of Hepatocyte-Stromal Crosstalk in the Early Premalignant Microenvironment of HBV-Associated HCC.International journal of molecular sciences · 2026Review
- Akkermansia: A Potential Target for Natural Botanicals in Treatment of Nonalcoholic Fatty Liver Diseases.Chinese journal of integrative medicine · 2026Review
- Total Flavonoids of Litchi chinensis Sonn. Seed Improves Hepatic Fibrosis by Inhibiting PANoptosis.Chinese journal of integrative medicine · 2026Article
- The value ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- 3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening.Pharmacology research & perspectives · 2026Review
- Systemic Ammonia Toxicity: An Underestimated Driver of Cerebral Energy Crisis in Hepatic Encephalopathy.International journal of molecular sciences · 2026Review
575 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global health. Correlating with liver disease progression, fibrosis is a key factor for liver disease outcome and risk of hepatocellular carcinoma (HCC). Despite different mechanism of primary liver injury and disease-specific cell responses, the progression of fibrotic liver disease follows shared patterns across the main liver disease etiologies. Scientific discoveries within the last decade have transformed the understanding of the mechanisms of liver fibrosis. Removal or elimination of the causative agent such as control or cure of viral infection has shown that liver fibrosis is reversible. However, reversal often occurs too slowly or too infrequent to avoid life-threatening complications particularly in advanced fibrosis. Thus, there is a huge unmet medical need for anti-fibrotic therapies to prevent liver disease progression and HCC development. However, while many anti-fibrotic candidate agents have shown robust effects in experimental animal models, their anti-fibrotic effects in clinical trials have been limited or absent. Thus, no approved therapy exists for liver fibrosis. In this review we summarize cellular drivers and molecular mechanisms of fibrogenesis in chronic liver diseases and discuss their impact for the development of urgently needed anti-fibrotic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.